Thomas John T

Director Thomas John T bought 1,450 shares of DOC at $17.06 on 2025-08-06 ($24,729.75); prior buy at same ticker was underwater.

Thomas John T, a director, purchased 1,450 shares at $17.06, increasing his holdings from 808.6K to 810.0K shares. His prior buy at this ticker on 2025-04-28 delivered a 90-day return of -1.4%, placing this transaction in the context of a track record where 0 of 1 prior buys were well-timed at the 90-day mark. The stock has declined 27.1% from its 52-week high of $23.12 and is trading below the transaction price at the current $16.85. The purchase size represents only 0.2% of his existing holdings, suggesting a marginal position adjustment rather than a material conviction-driven accumulation in a healthcare REIT that carries a P/E of 70.21.

Director Thomas John T bought 4,200 shares of DOC at $17.84; 4 other insiders bought within 14 days amid -23.2% decline from 52-week high.

Director Thomas John T purchased 4,200 shares at $17.84 on 2025-04-28, increasing holdings from 809,366 shares to 813,566 shares. Notably, 4 other insiders also bought within the past 14 days, forming a cluster buy pattern. The stock is trading at $17.75 current price, representing a -23.2% decline from the 52-week high of $23.12, with a 30-day decline of -12.1% and 90-day decline of -14.1%. The company shows solid fundamentals with revenue of $702,889,000.00 (latest quarter) and net income of $42,828,000.00, though the P/E of 44.38 suggests the stock may be valued for significant future growth. The coordinated buying activity by multiple insiders during a period of pronounced price weakness warrants monitoring to assess whether this reflects differentiated information or conviction among the company's leadership.